APM: AI 评分 43/100 — AI 分析 (4月 2026)

Aptorum Group Limited is a biopharmaceutical company focused on developing therapeutics and diagnostics for infectious diseases and cancer. The company's pipeline includes products targeting neuroblastoma, coronavirus, MRSA, influenza, and other diseases.

Key Facts: Price: $0.97 AI Score: 43/100 Sector: Healthcare

公司概况

概要：

Aptorum Group Limited pioneers novel therapeutics and diagnostics for infectious diseases and cancer, leveraging innovative platforms to address unmet medical needs. With a diverse pipeline and strategic focus, Aptorum seeks to deliver transformative healthcare solutions and enhance patient outcomes, though significant risks remain.

APM是做什么的？

Aptorum Group Limited, established in 2010 and headquartered in London, is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutic products and diagnostics. The company operates through two segments: Therapeutics and Non-Therapeutics. Aptorum's core focus lies in addressing unmet medical needs in infectious diseases and cancer. Its pipeline showcases a range of innovative products, including SACT-1 for neuroblastoma and other cancer types, SACT-COV19 for the treatment of coronavirus disease, ALS-4 targeting bacterial infections caused by Staphylococcus aureus (including MRSA), and ALS-1 for viral infections caused by influenza virus A. Beyond these lead candidates, Aptorum is also developing ALS-2/3 for gram-positive bacterial infections, RPIDD (a pathogen molecular diagnostic), NativusWell DOI (NLS-2) as a dietary supplement, NLS-1 for endometriosis, DLS-1+2 to treat NSCLC with mutation, DLS-3 (an autoimmune small molecule), and CLS-1 for obesity. The company's research and development efforts are underpinned by proprietary platforms that enable the systematic screening of existing approved drug molecules and microbiome-based research for metabolic diseases. Aptorum also operates a medical clinic, further integrating its research and clinical activities. Aptorum aims to expand its therapeutic and diagnostic horizons into neurology, gastroenterology, metabolic disorders, women's health, and other significant disease areas.

APM的投资论点是什么？

Investing in Aptorum Group Limited presents a high-risk, high-reward opportunity. The company's diverse pipeline, targeting significant unmet needs in infectious diseases and cancer, offers substantial potential upside. Key value drivers include successful clinical trials and regulatory approvals for its lead candidates, particularly SACT-1 and ALS-4. However, the company's limited financial resources and reliance on future funding introduce significant uncertainty. A successful outcome hinges on Aptorum's ability to secure partnerships, advance its pipeline through clinical development, and ultimately commercialize its products. The current P/E ratio of -2.85 reflects the company's pre-profitability status, emphasizing the speculative nature of this investment. The company's market cap is $0.01B as of 2026-03-02.

APM在哪个行业运营？

Aptorum Group operates within the highly competitive biotechnology industry, characterized by rapid innovation, stringent regulatory requirements, and substantial financial risks. The market for cancer therapeutics and infectious disease treatments is vast and growing, driven by aging populations and increasing prevalence of drug-resistant pathogens. Aptorum competes with established pharmaceutical giants and numerous smaller biotech firms, including AEON, BOLT, CING, CLRB and COCP, all vying for market share. Success in this industry requires a combination of scientific expertise, robust clinical trial data, and effective commercialization strategies.

Healthcare/Biotechnology

Healthcare

APM有哪些增长机遇？

SACT-1 Development for Neuroblastoma: Aptorum's SACT-1 targets neuroblastoma, a rare pediatric cancer with limited treatment options. The global neuroblastoma market is projected to reach $1.8 billion by 2028. Successful clinical trials and FDA approval could position SACT-1 as a key player in this market, offering a significant growth opportunity for Aptorum. Timeline: Ongoing clinical trials with potential for accelerated approval pathways.
ALS-4 for MRSA Infections: ALS-4 addresses bacterial infections, including MRSA, a growing concern due to antibiotic resistance. The global market for MRSA treatment is expected to reach $4.5 billion by 2027. ALS-4's novel mechanism of action could provide a competitive advantage. Timeline: Ongoing preclinical and clinical development with potential for market entry within 3-5 years.
RPIDD Pathogen Molecular Diagnostic: The RPIDD pathogen molecular diagnostic represents a significant opportunity in the infectious disease diagnostics market. This market is driven by the need for rapid and accurate detection of pathogens, estimated to reach $12 billion by 2025. Successful development and commercialization could provide a recurring revenue stream for Aptorum. Timeline: Development and regulatory approval anticipated within 2-3 years.
Expansion into Women's Health with NLS-1: NLS-1 targets endometriosis, a prevalent women's health condition with limited treatment options. The endometriosis market is projected to reach $3 billion by 2027. NLS-1's potential to address unmet needs in this market could drive significant growth for Aptorum. Timeline: Preclinical development with potential for clinical trials within 2 years.
Therapeutic and Diagnostic Projects in Neurology: Aptorum is expanding into neurology, focusing on therapeutic and diagnostic projects. The global neurology market is experiencing substantial growth, driven by an aging population and increasing prevalence of neurological disorders. This expansion could diversify Aptorum's pipeline and create new revenue streams. Timeline: Ongoing research and development with potential for clinical candidates within 3-5 years.

Aptorum Group operates in the Therapeutics and Non-Therapeutics segments, diversifying its revenue streams.
The company's pipeline includes SACT-1 for neuroblastoma, addressing a critical unmet need in cancer treatment.
Aptorum is developing ALS-4 to combat bacterial infections, including MRSA, a growing global health concern.
The company is exploring microbiome-based research platforms for treating metabolic diseases, showcasing innovative approaches.
Aptorum operates a medical clinic, integrating research with clinical practice.

APM提供哪些产品和服务？

Discovers and develops therapeutic products for infectious diseases.
Creates cancer treatments.
Develops diagnostic tools for pathogen detection.
Focuses on unmet medical needs in neurology, gastroenterology, and women's health.
Operates a medical clinic.
Engages in microbiome-based research for metabolic diseases.

APM如何赚钱？

Develops and licenses therapeutic candidates.
Generates revenue through the sale of diagnostic products.
Provides medical services through its clinic.
Out-licenses or partners for late-stage development and commercialization.

Patients suffering from infectious diseases and cancer.
Hospitals and clinics using diagnostic tools.
Pharmaceutical companies licensing therapeutic candidates.
Consumers purchasing dietary supplements.

Proprietary drug discovery platforms.
Patent protection for key therapeutic candidates.
Expertise in infectious diseases and cancer biology.
Integrated research and clinical operations through its medical clinic.

什么因素可能推动APM股价上涨？

Upcoming: Clinical trial results for SACT-1 in neuroblastoma.
Upcoming: Regulatory submissions for RPIDD pathogen molecular diagnostic.
Ongoing: Progress in preclinical development of ALS-4 for MRSA infections.
Ongoing: Expansion of therapeutic and diagnostic projects in neurology.

APM的主要风险是什么？

Potential: Dilution of existing shareholders through future funding rounds.
Ongoing: High cash burn rate due to research and development expenses.
Potential: Failure of clinical trials for key pipeline candidates.
Potential: Regulatory delays or rejections.
Ongoing: Competition from larger pharmaceutical companies with greater resources.

APM的核心优势是什么？

Diverse pipeline of therapeutic and diagnostic candidates.
Proprietary drug discovery platforms.
Focus on unmet medical needs.
Integrated research and clinical operations.

APM的劣势是什么？

Limited financial resources.
Reliance on future funding.
Early-stage development of many pipeline candidates.
Small employee base.

APM有哪些机遇？

Strategic partnerships with larger pharmaceutical companies.
Successful clinical trials and regulatory approvals.
Expansion into new therapeutic areas.
Increased demand for diagnostic tools.

APM面临哪些威胁？

Competition from established pharmaceutical companies.
Regulatory hurdles and clinical trial failures.
Patent expirations.
Economic downturns affecting healthcare spending.

APM的竞争对手是谁？

Aeon Biopharma, Inc. — Focuses on botulinum toxin products. — (AEON)
Bolt Biotherapeutics, Inc. — Develops immuno-oncology therapies. — (BOLT)
Cingulate Inc. — Develops therapies for ADHD. — (CING)
Cellectar Biosciences, Inc. — Focuses on cancer therapeutics and diagnostics. — (CLRB)
Cocrystal Pharma, Inc. — Develops antiviral therapeutics. — (COCP)

Key Metrics

Price: $0.97 (-4.89%)
Market Cap: $7
Volume: NaN
MoonshotScore: 43/100

常见问题

What does Aptorum Group Limited (APM) do?

Aptorum Group Limited (APM) is a biopharmaceutical company focused on discovering, developing, and commercializing therapeutic products and diagnostics to address unmet medical needs, particularly in infectious diseases and cancer. The company's pipeline includes products like SACT-1 for neuroblastoma, ALS-4 for MRSA infections, and RPIDD, a pathogen molecular diagnostic. Aptorum operates through therapeutics and non-therapeutics segments, aiming to deliver innovative healthcare solutions through internal research and strategic partnerships.

Is APM stock a good buy?

Evaluating whether APM stock is a good buy requires careful consideration. While Aptorum has a diverse pipeline and focuses on high-growth markets, its limited financial resources and early-stage development programs present significant risks. The company's negative P/E ratio of -2.85 reflects its current lack of profitability. Investors should weigh the potential for high returns against the substantial risks of clinical trial failures, regulatory hurdles, and the need for additional funding before considering APM a worthwhile investment.

What are the main risks for APM?

The main risks for Aptorum Group Limited (APM) include potential dilution of existing shareholders through future funding rounds, a high cash burn rate associated with ongoing research and development activities, and the possibility of clinical trial failures for its key pipeline candidates. Regulatory delays or rejections also pose a significant risk, as does competition from larger pharmaceutical companies with greater resources. These factors contribute to the company's classification as a medium-risk investment.

What catalysts could move APM stock?

Several catalysts could potentially move APM stock. Positive clinical trial results for SACT-1 in neuroblastoma could significantly boost investor confidence. Regulatory submissions and approvals for products like the RPIDD pathogen molecular diagnostic could also drive stock appreciation. Furthermore, any progress in preclinical development of ALS-4 for MRSA infections or expansion into new therapeutic areas like neurology could serve as positive catalysts for APM stock.

What is APM stock price target?

As of March 2, 2026, there is no readily available analyst consensus price target for APM stock due to its micro-cap status and limited analyst coverage. A fair value estimate would require a detailed analysis of Aptorum's pipeline, clinical trial progress, potential market opportunities, and financial projections, discounted for the inherent risks associated with biotechnology companies. Investors should conduct their own due diligence or consult with a financial advisor to determine a suitable price target based on their individual risk tolerance and investment objectives.

Is APM a good investment right now?

Use the AI score and analyst targets on this page to evaluate Aptorum Group Limited (APM). Our analysis considers fundamentals, technicals, and market sentiment to help you decide.

What is the MoonshotScore for APM?

The MoonshotScore is a proprietary 0-100 AI rating that evaluates Aptorum Group Limited across multiple dimensions including financial health, growth trajectory, and risk factors.

Where can I find APM financial statements?

Aptorum Group Limited financial data including revenue, earnings, and balance sheet metrics are available in the Financials tab on this page, sourced from institutional-grade data providers.